書誌事項
- タイトル別名
-
- Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma
- リンショウ ケンキュウ タハツセイ コツズイシュ カンジャ ノ マッショウケツ カンサイボウ サイシュ ニ タイスル bortezomib オ フクム ドウニュウ リョウホウ ノ エイキョウ
この論文をさがす
抄録
A high dose of melphalan followed by autologous stem cell transplantation (ASCT) is considered as the standard therapy for multiple myeloma. For induction therapy, 78 patients received conventional regimens (control group) and 32 patients received bortezomib-containing regimens (bortezomib group). We retrospectively compared the yield of harvested CD34+ cells between the two groups. In order to mobilize CD34+ cells, 83% of the control group and 63% of the bortezomib group received a high dose of cyclophosphamide followed by G-CSF, and 12% of the control group received a high dose of etoposide instead of cyclophosphamide. Furthermore, 5% of the control group and 38% of the bortezomib group received G-CSF alone for CD34+ cell mobilization. Overall, the yield of CD34+ cells was higher in the control group than in the bortezomib group (7.4 vs. 5.2×106/kg, P=0.004). Regarding the patients mobilized by a high dose of cyclophosphamide followed by G-CSF, the rate of achieving CD34+ cells >2.0×106 cells/kg was similar. Bortezomib did not significantly affect the successful collection of at least CD34+ cells > 2.0×106 cells/kg after mobilization with a high dose of cyclophosphamide followed by G-CSF.
収録刊行物
-
- 臨床血液
-
臨床血液 54 (1), 109-116, 2013
一般社団法人 日本血液学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282680013197056
-
- NII論文ID
- 10031147827
- 130004501732
-
- NII書誌ID
- AN00252940
-
- COI
- 1:STN:280:DC%2BC3szmsFCjuw%3D%3D
-
- ISSN
- 18820824
- 04851439
-
- NDL書誌ID
- 024248199
-
- PubMed
- 23391654
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDL
- PubMed
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可